Five Prime

Five Prime

[Translate to English:]

Five Prime has a discovery platform that includes a library of over 5700 human extracellular proteins, generated by a proprietary technology that enables the capture of cDNAs with intact 5 prime ends. I It also has developed a range of proprietary screens and characterization tools, including automated cell-based screening systems and a rapid in vivo protein production system, to take advantage of its library and overcome limitations of traditional protein screening methods. Via this platform, the company has isolated the 700 proteins that drive immune cell interactions. The key drug in development is FPA008, a humanized IgG4 anti-CSF1R (macrophage colony stimulating factor) antibody. The lead indication for FPA008 is pigmented villonodular synovitis (PVNS), a macrophage-driven tumor. The company began a Phase II trial in May 2016 and we expect more data in mid-2018. The larger potential for FPA008 is as a combination partner with other immuno-oncology agents. A Phase I/II trial investigating FPA008 as a single agent and in combination with Bristol-Myers’ Opdivo is ongoing, and first results from the combination portion showed promise in pancreatic cancer. More data in other solid tumor types are expected in 2018. The company is also developing FPA144, a proprietary ADCC-engineered antibody that inhibits FGFR2b. We expect the start of a Phase III trial in gastric cancer in 2018.